ULTOMIRIS (Alexion Pharmaceuticals Australasia Pty Ltd)
Product name
ULTOMIRIS
Date registered
Evaluation commenced
Decision date
Approval time
108 (120 working days)
Active ingredients
ravulizumab
Registration type
EOI
Indication
Ultomiris is indicated:
- for the treatment of patients with Paroxysmal Nocturnal Haemoglobinuria (PNH)
- for the treatment of patients with Atypical Haemolytic Uraemic Syndrome (aHUS)